Abstract:Background: Periodontitis and post-menopausal osteoporosis include common chronic bone disorders worldwide, with similar etiopathogenetic events. This study evaluated the effect of systemic melatonin administration on the alveolar bone destruction of periodontitis progression in an experimental periodontitis model in osteoporotic rats. Methods: Forty-four Wistar rats were randomly divided into six experimental groups: control (C; n = 6); osteoporosis (O; n = 6); ligated periodontitis (LP; n = 8); osteoporosis- and periodontitis-induced (O+LP; n = 8); osteoporosis- and periodontitis-induced through 30 mg/kg/day melatonin administration (ML30; n = 8); and osteoporosis- and periodontitis-induced through 50 mg/kg/day melatonin administration (ML50; n = 8). The rats underwent bilateraloophorectomy and were maintained for 4 months to induce osteoporosis. After 4 months, 4-0 silk ligatures were placed submarginally around the mandibular first molar of each rat to induce experimental periodontitis, and melatonin was administered in the ML30 and ML50 groups for 30 days. Changes in alveolar bone levels were clinically measured, and tissues were histopathologically examined. Results: Osteoclastic activity in the LP and O+LP groups was significantly higher than in the other groups (p 0.05). RANKL activity was the highest in the O+LP group, while melatonin decreased RANKL activity in the melatonin-administered groups (p < 0.05). Systemically administered melatonin significantly decreased alveolar bone loss in the ML30 and ML50 groups compared with that in the periodontitis groups (p < 0.05). Conclusions: Melatonin inhibited alveolar bone destruction by decreasing the RANKL expression and inflammatory cell infiltration and increased osteoblastic activity in a rat model with osteoporosis and periodontitis.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the effect of melatonin on alveolar bone destruction in experimental rat models of periodontitis and osteoporosis. Specifically, the researchers hope to systematically administer different doses of melatonin (30 mg/kg and 50 mg/kg) to observe whether it can reduce alveolar bone loss caused by periodontitis and osteoporosis and explore its mechanism of action. ### Background 1. **Periodontitis** is a chronic inflammatory disease related to the imbalance of plaque biofilm, which leads to the progressive destruction of tooth - supporting tissues. 2. **Osteoporosis** is a bone disease that weakens bones by reducing bone density and increasing bone fragility, increasing the risk of fractures. 3. Both diseases involve chronic inflammation and changes in bone metabolism, and oxidative stress plays an important role in these processes. 4. Melatonin is a potent antioxidant with anti - inflammatory effects, which can inhibit bone resorption and promote bone formation. ### Research Objectives - **Evaluate the effect of melatonin on alveolar bone destruction**: Through rat models of experimental periodontitis and osteoporosis, study whether melatonin can reduce alveolar bone loss. - **Explore the mechanism of action of melatonin**: Analyze how melatonin exerts its effect by inhibiting RANKL expression and reducing inflammatory cell infiltration. ### Methods - **Animal models**: Use 44 female Wistar rats and divide them into 6 experimental groups: - Control group (C) - Osteoporosis group (O) - Periodontitis group (LP) - Osteoporosis and periodontitis group (O + LP) - 30 mg/kg melatonin group (ML30) - 50 mg/kg melatonin group (ML50) - **Experimental procedures**: - Induce osteoporosis by bilateral ovariectomy. - Induce periodontitis by placing silk ligatures around the mandibular first molars. - Administer different doses of melatonin for 30 days. - **Detection methods**: - Measure alveolar bone loss. - Conduct histopathological examinations, including osteoclasts, osteoblasts counting and RANKL immunohistochemical staining. ### Results - **Alveolar bone loss**: The alveolar bone loss in the LP group and the O + LP group was significantly higher than that in other groups, while the alveolar bone loss in the ML30 and ML50 groups was significantly reduced. - **Osteoclast counting**: The number of osteoclasts in the LP group and the O + LP group was the highest, while the number of osteoclasts in the ML30 and ML50 groups was significantly reduced. - **RANKL expression**: The RANKL expression in the O + LP group was the highest, while the RANKL expression in the melatonin - treated groups was significantly decreased. - **Osteoblast counting**: The number of osteoblasts in the ML30 group was the highest, indicating that melatonin promoted bone formation. ### Conclusion Melatonin effectively inhibits alveolar bone destruction in rat models of periodontitis and osteoporosis by reducing RANKL expression and inflammatory cell infiltration and increasing osteoblast activity. This suggests that melatonin may be a potential drug for the treatment of these two diseases.

Melatonin Decreases Alveolar Bone Loss in Rats with Experimental Periodontitis and Osteoporosis: A Morphometric and Histopathologic Study

The Effect of Astragalus Extractive on Alveolar Bone Rebuilding Progress of Tooth Extracted Socket of Ovariectomied Rats.

REPARATIVE EFFECT OF MELATONIN ON THE MANDIBULAR ALVEOLAR BONE AND GINGIVA OF RATS WITH INDUCED PERIODONTITIS

Melatonin Prevents Bone Destruction in Mice with Retinoic Acid–induced Osteoporosis

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

Melatonin increases bone mass in normal, perimenopausal, and postmenopausal osteoporotic rats via the promotion of osteogenesis

Preventive effects of melatonin on periodontal tissue destruction due to psychological stress in rats with experimentally induced periodontitis

Melatonin Restores the Osteoporosis-Impaired Osteogenic Potential of Bone Marrow Mesenchymal Stem Cells by Preserving SIRT1-mediated Intracellular Antioxidant Properties.

Effects of melatonin against experimentally induced apical periodontitis in rats

Prophylactic supplement with melatonin successfully suppresses the pathogenesis of periodontitis through normalizing RANKL/OPG ratio and depressing the TLR4/MyD88 signaling pathway

Melatonin Attenuates Titanium Particle-Induced Osteolysis Via Activation of Wnt/β-catenin Signaling Pathway

Melatonin Accelerates Osteoporotic Bone Defect Repair by Promoting Osteogenesis–Angiogenesis Coupling

Impact of Photobiomodulation and Melatonin on Periodontal Healing of Periodontitis in Immunosuppressed Rats

Effects of oestrogen deficiency on the alveolar bone of rats with experimental periodontitis

Melatonin prevents bone loss in osteoporotic rats with valproic acid treatment by anti-inflammatory and anti-oxidative stress

Melatonin alleviates hydrogen peroxide induced oxidative damage in MC3T3-E1 cells and promotes osteogenesis by activating SIRT1

Melatonin Increases Bone Mass Around the Prostheses of OVX Rats by Ameliorating Mitochondrial Oxidative Stress Via the SIRT3/SOD2 Signaling Pathway

Additive Benefits of Melatonin on Osteogenic Differentiation Rate and Osteogenic Potential Quantified by Alkaline Phosphatase - A Systematic Review

Melatonin suppresses bone marrow adiposity in ovariectomized rats by rescuing the imbalance between osteogenesis and adipogenesis through SIRT1 activation

Biological effects of melatonin on osteoblast/osteoclast cocultures, bone, and quality of life: Implications of a role for MT2 melatonin receptors, MEK1/2, and MEK5 in melatonin-mediated osteoblastogenesis

Inhibitory effects of melatonin on titanium particle-induced inflammatory bone resorption and osteoclastogenesis via suppression of NF-κB signaling.